CIK: 0001381843
Total reported value
$309.7M
Reporting period: 2026-03-31 · Number of holdings: 39
Atle Fund Management AB disclosed 39 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $309.7M and a quarterly turnover rate of 32.2%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "A"
Atle Fund Management AB's disclosed holdings carry a Herfindahl concentration index of 0.036 — mathematically equivalent to about 28 equally-sized positions, close to its 39 actual disclosed holdings. Value is spread relatively evenly across the portfolio rather than concentrated in a handful of names.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.65), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Trim ABBV
0.0% -$14.3M
Trim LLY
+27.6% -$6.6M
Trim NBIX
-5.4% -$5.6M
Trim ISRG
+217.4% -$3.2M
Trim TMO
-23.2% -$2.9M
Add MRK
-82.7% $2.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 8.67% | -2.00% | +27.59% | |
| 2 | MRK | Merck & Co. INC. | Stock-Healthcare | 7.40% | +0.83% | -82.71% | |
| 3 | TMO | Thermo Fisher Scientific INC | Stock-Healthcare | 4.67% | -0.86% | -23.16% | |
| 4 | ONC | Beone Medicines Ltd-adr | Stock-Other | 3.92% | — | +3.18% | |
| 5 | JNJ | Johnson & Johnson | Stock-Healthcare | 3.86% | +3.86% | NEW | |
| 6 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 3.84% | +0.39% | -21.18% | |
| 7 | VRTX | Vertex Pharmaceuticals INC | Stock-Healthcare | 3.61% | +0.29% | — | |
| 8 | ABBV | Abbvie INC | Stock-Healthcare | 3.35% | -4.54% | — | |
| 9 | SYK | Stryker CORP | Stock-Healthcare | 3.09% | +0.08% | — | |
| 10 | ISRG | Intuitive Surgical INC | Stock-Healthcare | 3.05% | -0.98% | +217.40% | |
| 11 | IONS | Ionis Pharmaceuticals INC | Stock-Healthcare | 3.03% | +0.70% | -69.83% | |
| 12 | MIRM | Mirum Pharmaceuticals INC | Stock-Other | 3.03% | +0.77% | +118.28% | |
| 13 | CVS | Cvs Health CORP | Stock-Healthcare | 2.99% | +0.29% | -77.68% | |
| 14 | RVMD | Revolution Medicines INC | Stock-Healthcare | 2.93% | +0.64% | +584.43% | |
| 15 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.86% | -0.45% | -62.80% | |
| 16 | AMGN | Amgen INC | Stock-Healthcare | 2.81% | +0.52% | — | |
| 17 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.67% | +2.67% | NEW | |
| 18 | ALKS | Alkermes plc | Stock-Healthcare | 2.66% | +0.50% | — | |
| 19 | INCY | Incyte CORP | Stock-Healthcare | 2.57% | +0.34% | -28.31% | |
| 20 | NBIX | Neurocrine Biosciences INC | Stock-Healthcare | 2.54% | -1.75% | -5.39% | |
| 21 | GILD | Gilead Sciences INC | Stock-Healthcare | 2.31% | +0.32% | -5.57% | |
| 22 | KRYS | Krystal Biotech INC | Stock-Healthcare | 2.19% | -0.47% | +11.01% | |
| 23 | COR | Cencora INC | Stock-Healthcare | 2.13% | -0.43% | -1.27% | |
| 24 | IRTC | Irhythm Holdings INC | Stock-Healthcare | 2.02% | -0.11% | -40.60% | |
| 25 | INSM | Insmed INC | Stock-Healthcare | 1.92% | +0.37% | +249.58% | |
| 26 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 1.78% | -0.43% | -51.89% | |
| 27 | CELC | Celcuity INC | Stock-Other | 1.66% | +0.33% | +237.78% | |
| 28 | ABVX | Abivax Sa-adr | Stock-Other | 1.54% | +0.18% | — | |
| 29 | CAH | Cardinal Health INC | Stock-Healthcare | 1.54% | — | +363.07% | |
| 30 | IDYA | Ideaya Biosciences INC | Stock-Other | 1.30% | +0.23% | -68.05% | |
| 31 | TNGX | Tango Therapeutics INC | Stock-Other | 1.17% | +1.17% | NEW | |
| 32 | SYRE | Spyre Therapeutics INC | Stock-Other | 1.13% | +1.13% | NEW | |
| 33 | IRON | Disc Medicine INC | Stock-Other | 1.03% | -0.19% | +123.60% | |
| 34 | CMPX | Compass Therapeutics INC | Stock-Other | 0.99% | -0.01% | -92.84% | |
| 35 | UNH | Unitedhealth Group INC | Stock-Healthcare | 0.90% | -0.12% | — | |
| 36 | DXCM | Dexcom INC | Stock-Healthcare | 0.85% | +0.01% | +1371.05% | |
| 37 | BCAX | Bicara Therapeutics INC | Stock-Other | 0.75% | +0.15% | +950.29% | |
| 38 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 0.71% | -0.22% | +43.75% | |
| 39 | PYXS | Pyxis Oncology INC | Stock-Other | 0.52% | +0.29% | -68.08% |
Performance for Q3 2026
+14.9%
Performance Last 4 Quarters
+32%
Based on 55% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 39 | $309.7M | 32 | |
| 2025-12-31 | 39 | $313.4M | 100 | |
| 2025-09-30 | 38 | $27.0M | 100 | |
| 2025-06-30 | 37 | $233.7M | 0 | |
| 2025-03-31 | 37 | $226.5M | 100 | |
| 2024-12-31 | 36 | $210.8M | 0 | |
| 2024-09-30 | 36 | $212.8M | 0 | |
| 2024-06-30 | 38 | $164.0M | 0 | |
| 2024-03-31 | 44 | $164.4M | 0 | |
| 2023-12-31 | 45 | $127.8M | 0 | |
| 2022-12-31 | 53 | $51.8M | 0 | |
| 2022-09-30 | 10 | $47.3M | 0 | |
| 2022-06-30 | 12 | $43.4M | 0 | |
| 2022-03-31 | 12 | $62.8M | 0 | |
| 2021-12-31 | 13 | $71.0M | 0 | |
| 2021-09-30 | 17 | $66.8M | 0 | |
| 2021-06-30 | 9 | $105.5M | 100 | |
| 2021-03-31 | 15 | $125.6M | 69 | |
| 2020-12-31 | 17 | $151.0M | 100 | |
| 2017-12-31 | 16 | $47.4M | 90 | |
| 2017-09-30 | 12 | $85.6M | 42 | |
| 2017-06-30 | 11 | $80.2M | 93 | |
| 2017-03-31 | 10 | $65.2M | 100 | |
| 2016-12-31 | 15 | $108.5M | 67 | |
| 2016-09-30 | 15 | $134.4M | 68 | |
| 2016-06-30 | 18 | $218.1M | 42 | |
| 2016-03-31 | 18 | $213.6M | 70 | |
| 2015-12-31 | 14 | $212.5M | 63 | |
| 2015-09-30 | 14 | $169.1M | 55 | |
| 2015-06-30 | 14 | $195.7M | 48 | |
| 2015-03-31 | 15 | $144.4M | 39 | |
| 2014-12-31 | 16 | $121.0M | 81 | |
| 2014-09-30 | 16 | $137.1M | 34 | |
| 2014-06-30 | 19 | $177.6M | 32 | |
| 2014-03-31 | 18 | $140.3M | 71 | |
| 2013-12-31 | 18 | $100.5M | — |
Atle Fund Management AB's most significant position changes for 2026-03-31: New buy: Johnson & Johnson (JNJ); New buy: Edwards Lifesciences CORP (EW); Sold out: Ufp Technologies INC (UFPT); New buy: Tango Therapeutics INC (TNGX); New buy: Spyre Therapeutics INC (SYRE).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MRK | Merck & Co. INC. | +0.8% | -82.71% | Trim |
| 2 | MIRM | Mirum Pharmaceuticals INC | +0.8% | +118.28% | Add |
| 3 | IONS | Ionis Pharmaceuticals INC | +0.7% | -69.83% | Trim |
| 4 | RVMD | Revolution Medicines INC | +0.6% | +584.43% | Add |
| 5 | AMGN | Amgen INC | +0.5% | — | Unchanged |
| 6 | ALKS | Alkermes plc | +0.5% | — | Unchanged |
| 7 | BBIO | Bridgebio Pharma INC | +0.4% | -21.18% | Trim |
| 8 | INSM | Insmed INC | +0.4% | +249.58% | Add |
| 9 | INCY | Incyte CORP | +0.3% | -28.31% | Trim |
| 10 | CELC | Celcuity INC | +0.3% | +237.78% | Add |
| 11 | GILD | Gilead Sciences INC | +0.3% | -5.57% | Trim |
| 12 | PYXS | Pyxis Oncology INC | +0.3% | -68.08% | Trim |
| 13 | CVS | Cvs Health CORP | +0.3% | -77.68% | Trim |
| 14 | VRTX | Vertex Pharmaceuticals INC | +0.3% | — | Unchanged |
| 15 | IDYA | Ideaya Biosciences INC | +0.2% | -68.05% | Trim |
| 16 | ABVX | Abivax Sa-adr | +0.2% | — | Unchanged |
| 17 | BCAX | Bicara Therapeutics INC | +0.2% | +950.29% | Add |
| 18 | SYK | Stryker CORP | +0.1% | — | Unchanged |
| 19 | DXCM | Dexcom INC | 0% | +1371.05% | Add |
| 20 | ONC | Beone Medicines Ltd-adr | — | +3.18% | Add |
| 21 | CAH | Cardinal Health INC | — | +363.07% | Add |
| 22 | CMPX | Compass Therapeutics INC | 0% | -92.84% | Trim |
| 23 | IRTC | Irhythm Holdings INC | -0.1% | -40.60% | Trim |
| 24 | UNH | Unitedhealth Group INC | -0.1% | — | Unchanged |
| 25 | IRON | Disc Medicine INC | -0.2% | +123.60% | Add |
| 26 | SLNOEUR | Soleno Therapeutics INC | -0.2% | +43.75% | Add |
| 27 | COR | Cencora INC | -0.4% | -1.27% | Trim |
| 28 | NAMS | NewAmsterdam Pharma Company N.V. | -0.4% | -51.89% | Trim |
| 29 | BSX | Boston Scientific CORP | -0.5% | -62.80% | Trim |
| 30 | KRYS | Krystal Biotech INC | -0.5% | +11.01% | Add |
| 31 | TMO | Thermo Fisher Scientific INC | -0.9% | -23.16% | Trim |
| 32 | ISRG | Intuitive Surgical INC | -1% | +217.40% | Add |
| 33 | NBIX | Neurocrine Biosciences INC | -1.8% | -5.39% | Trim |
| 34 | LLY | Eli Lilly & Co | -2% | +27.59% | Add |
| 35 | ABBV | Abbvie INC | -4.5% | — | Unchanged |
| 36 | JNJ | Johnson & Johnson | — | NEW | New buy |
| 37 | EW | Edwards Lifesciences CORP | — | NEW | New buy |
| 38 | UFPT | Ufp Technologies INC | — | EXIT | Sold out |
| 39 | TNGX | Tango Therapeutics INC | — | NEW | New buy |
| 40 | SYRE | Spyre Therapeutics INC | — | NEW | New buy |
| 41 | ACLXGBX | Arcellx INC | — | EXIT | Sold out |
| 42 | AUTL | Autolus Therapeutics PLC | — | EXIT | Sold out |
| 43 | CRBP | Corbus Pharmaceuticals Holdi | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-11 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-06 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-04 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-07-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-05 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-04 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-12 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-04-25 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-01-30 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-10-21 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-07-08 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-05 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-01-18 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-08 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-10 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-04-30 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-05 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-09 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-13 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-07 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-04-28 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-01-24 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-10-24 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-07-26 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-04-19 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-01-11 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-10-13 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-07-20 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-04-20 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-01-21 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-10-14 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-07-17 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-04-23 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-02-05 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001666613
Total reported value
$309.6M
74 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001633625
Total reported value
$309.6M
67 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001691170
Total reported value
$309.8M
22 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001387980
Total reported value
$108.5M
117 stks
2015-09-30
Stale — no recent filing
3 of the top 5 holdings overlap, including Eli Lilly & Co
CIK 0000315032
Total reported value
$126.9B
197 stks
2026-03-31
2 of the top 5 holdings overlap, including Eli Lilly & Co
CIK 0000872259
Total reported value
$19.8B
327 stks
2026-03-31
2 of the top 5 holdings overlap, including Johnson & Johnson